94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Pharmacol.
Sec. Pharmacogenetics and Pharmacogenomics
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1574010
Deciphering Gene Mutations in the Efficacy and Toxicity of Antineoplastic Drugs: An Oncology Pharmacist's Perspective
Provisionally accepted- 1 Affiliated Hospital of Putian University, Putian, China
- 2 Dana-Farber Cancer Institution/Harvard Cancer Center, Boston, United States
Background/Objectives: This article reviews some key emerging pharmacogenomic topics in oncology pharmacy practice. Methods: Publications selected to review were mainly sourced from the new drug approvals by the Food and Drug Administration and the new regimens listed in the National Cancer Care Network. Results: Key pharmacogenomic topics were presented, including genetic alterations influencing drug metabolism, drug efficacy, and changes in therapeutic targeting; Relevant clinical updates and advancements were summarized to provide an in-depth understanding. Conclusions: The abundance of pharmacogenomic measures builds a solid foundation and heralds a paradigm shift toward individualized patient care.
Keywords: pharmacogenomics 1, cell-free DNA 2, circulating tumor DNA 3, Next-Generation Sequencing 4, precision medicine 5, tumor-agnostic drug 6
Received: 10 Feb 2025; Accepted: 10 Mar 2025.
Copyright: © 2025 Jiang and WEN. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yucai Jiang, Affiliated Hospital of Putian University, Putian, China
GUOLIN ALEXANDER WEN, Dana-Farber Cancer Institution/Harvard Cancer Center, Boston, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.